Patents by Inventor Jean-Guy Boiteau

Jean-Guy Boiteau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10533061
    Abstract: A hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent. A process of preparing a hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: January 14, 2020
    Assignee: Galderma S.A.
    Inventors: Jean-Guy Boiteau, Elin Säwén
  • Publication number: 20200002441
    Abstract: A new hydrogel made of double crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Double crosslinked glycosaminoglycans, one linkage via two ether bonds with a hydroxyl group of each of two glycosaminoglycans and another linkage via an alkoxyboronate ester anion formed between a boronate hemiester grafted to one of the glycosaminoglycans and a diol function of to the other glycosaminoglycan. The diol function may be a backbone diol function or a diol portion of a diol functional moiety grafted the other glycosaminoglycan.
    Type: Application
    Filed: August 2, 2017
    Publication date: January 2, 2020
    Applicants: Galderma Research & Development, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Rachel AUZELY-VELTY, Tamiris FIGUEIREDO, Laura JING JING, Craig Steven HARRIS, Jean-Guy BOITEAU, Thibaut GERFAUD, Loic TOMAS
  • Publication number: 20190233620
    Abstract: A hyaluronic acid product is comprising a cross-linked hyaluronic acid and one or more cyclodextrin molecules, and further comprising a guest molecule capable of forming a guest-host complex with the aminocyclodextrin molecule acting as a host, wherein the guest molecule is a retinoid, preferably adapalene, or a RAM BA. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent.
    Type: Application
    Filed: June 20, 2017
    Publication date: August 1, 2019
    Applicant: GALDERMA S.A.
    Inventors: Katarina EDSMAN, Jean-Guy BOITEAU
  • Patent number: 10343999
    Abstract: The present invention relates to a novel process for preparing enantiomerically pure compounds of N-(pyrid-4-yl)-2-hydroxyalkylamide type corresponding to the general formula (C) below: and also to processes for preparing the reaction intermediates used in this synthesis, said intermediates having the general formulae (A) and (B) below:
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: July 9, 2019
    Assignee: Galderma Research & Development
    Inventors: Jean-Guy Boiteau, Sebastien Daver, Nicolas Rodeville
  • Publication number: 20190169375
    Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 6, 2019
    Applicants: Galderma Research & Development, Centre National de la Recherche Scientifique
    Inventors: Rachel AUZELY-VELTY, Tamiris FIGUEIREDO, Laura JING JING, Craig Steven HARRIS, Jean-Guy BOITEAU, Thibaut GERFAUD, Loic TOMAS
  • Publication number: 20190023812
    Abstract: The invention relates to a hydrogel product comprising glycosaminoglycan molecules as the swellable polymer, wherein the glycosaminoglycan molecules are covalently crosslinked via crosslinks comprising a spacer group selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.
    Type: Application
    Filed: December 28, 2016
    Publication date: January 24, 2019
    Applicant: GALDERMA S.A.
    Inventors: Hotan MOJARRADI, Johan OLSSON, Craig Steven HARRIS, Jean-Guy BOITEAU, Thibaut GERFAUD, Loïc TOMAS
  • Publication number: 20190010124
    Abstract: The present invention relates to a novel process for preparing enantiomerically pure compounds of N-(pyrid-4-yl)-2-hydroxyalkylamide type corresponding to the general formula (C) below: and also to processes for preparing the reaction intermediates used in this synthesis, said intermediates having the general formulae (A) and (B) below:
    Type: Application
    Filed: November 8, 2016
    Publication date: January 10, 2019
    Applicant: Galderma Research & Development
    Inventors: Jean-Guy BOITEAU, Sébastien DAVER, Nicolas RODEVILLE
  • Publication number: 20180265600
    Abstract: A hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent. A process of preparing a hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules.
    Type: Application
    Filed: December 17, 2015
    Publication date: September 20, 2018
    Inventors: Jean-Guy BOITEAU, Elin Saewen
  • Patent number: 10047172
    Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) containing a functionalizing group including the step of reacting HA with a mixture of: (i) a first cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, and (ii) a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a second cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, to obtain a cross-linked HA containing the functionalizing group. The process provides a cross-linked hyaluronic acid (HA) containing a functionalizing group. The process utilizes a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a cross-linking agent.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: August 14, 2018
    Assignee: GALDERMA S.A.
    Inventor: Jean-Guy Boiteau
  • Patent number: 9908948
    Abstract: Enantiomers of butanediol diglycidyl ether (BDDE) are present in an enantiomerically enriched enantioenriched mixture of BDDE stereisomers or in an enantiomerically pure BDDE. Enantiomerically enriched or pure BDDE is useful as a cross-linking agent, such as in the preparation of a cross-linked hyaluronic acid product.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: March 6, 2018
    Assignee: GALDERMA S.A.
    Inventors: Jean-Guy Boiteau, Lars Nord, Thibaut Gerfaud
  • Publication number: 20170291963
    Abstract: Enantiomers of butanediol diglycidyl ether (BDDE) are present in an enantiomerically enriched enantioenriched mixture of BDDE stereisomers or in an enantiomerically pure BDDE. Enantiomerically enriched or pure BDDE is useful as a cross-linking agent, such as in the preparation of a cross-linked hyaluronic acid product.
    Type: Application
    Filed: August 28, 2015
    Publication date: October 12, 2017
    Applicant: GALDERMA S.A.
    Inventors: Jean-Guy BOITEAU, Lars NORD, Thibaut GERFAUD
  • Patent number: 9745281
    Abstract: A method is described for the synthesis of 4-(heterocycloalkyl)-benzene-1,3-diol compounds of general formulae (I) and (II): wherein X can be an oxygen atom or a sulphur atom. Also described, is a method for the synthesis of the reactive intermediates of general formula (7a) or (7b) Novel compounds as synthesis intermediates are also described.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: August 29, 2017
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Jean-Guy Boiteau
  • Publication number: 20170210829
    Abstract: A hydrogel product including a cross-linked polymer mixture of dextran cross-linked to hyaluronic acid, and one or more cyclodextrin molecules. The one or more cyclodextrin molecules are grafted onto the cross-linked polymer mixture, e.g. by amide bonds. The dextran may be cross-linked to the hyaluronic acid by ether bonds. The one or more cyclodextrin molecules may be grafted onto the cross-linked hyaluronic acid by amide bonds.
    Type: Application
    Filed: May 29, 2015
    Publication date: July 27, 2017
    Applicant: Galderma S.A.
    Inventor: Jean-Guy BOITEAU
  • Publication number: 20170196991
    Abstract: A hydrogel product including one or more cyclodextrin molecules grafted to hyaluronic acid and dextran, wherein the cyclodextrin-grafted hyaluronic acid is cross-linked to the dextran. The one or more cyclodextrin molecules are grafted, e.g. by amide bonds, to the hyaluronic acid prior to the cross-linking with dextran. The cyclodextrin-grafted hyaluronic acid may be cross-linked to the dextran by ether bonds.
    Type: Application
    Filed: May 29, 2015
    Publication date: July 13, 2017
    Applicant: GALDERMA S.A.
    Inventors: Jean-Guy BOITEAU, Helena LARKNER
  • Patent number: 9650337
    Abstract: A method is described for the synthesis of 4-piperidin-4-yl-benzene-1,3-diol of the following formula (I): and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: May 16, 2017
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Guy Boiteau, Branislav Musicki
  • Patent number: 9580412
    Abstract: Methods for preparing disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds that correspond to general formula (I) are described. Also described are pharmaceutical compositions that include the compounds, and methods of using the compounds and compositions for the treatment of chemokine-mediated diseases.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: February 28, 2017
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Jerôme Aubert, Jean-Guy Boiteau, Laurence Clary, Patricia Rossio, Marlène Schuppli-Nollet
  • Patent number: 9526732
    Abstract: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds represented by the general formula (I) are described. Also described, are pharmaceutical compositions including these compounds and the use of these compounds and compositions for the treatment of chemokine-mediated pathologies.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: December 27, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Jerôme Aubert, Jean-Guy Boiteau, Laurence Clary, Patricia Rossio, Marlène Schuppli-Nollet
  • Publication number: 20160362403
    Abstract: Methods for preparing disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds that correspond to general formula (I) are described. Also described are pharmaceutical compositions that include the compounds, and methods of using the compounds and compositions for the treatment of chemokine-mediated diseases.
    Type: Application
    Filed: June 7, 2016
    Publication date: December 15, 2016
    Inventors: Branislav MUSICKI, Jerôme AUBERT, Jean-Guy BOITEAU, Laurence CLARY, Patricia ROSSIO, Marlène SCHUPPLI-NOLLET
  • Publication number: 20160237177
    Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) containing a functionalizing group including the step of reacting HA with a mixture of: (i) a first cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, and (ii) a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a second cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, to obtain a cross-linked HA containing the functionalizing group. The process provides a cross-linked hyaluronic acid (HA) containing a functionalizing group. The process utilizes a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a cross-linking agent.
    Type: Application
    Filed: September 30, 2014
    Publication date: August 18, 2016
    Applicant: GALDERMA S.A.
    Inventor: Jean-Guy BOITEAU
  • Patent number: 9415039
    Abstract: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to general formula (I) are disclosed. Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: August 16, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Jerôme Aubert, Patricia Rossio, Marlène Schuppli-Nollet, Laurence Clary, Jean-Guy Boiteau